Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate
Authors:
- Vincent Q. TrinhVTVincent Q. Trinh
- Nazim BenzerdjebNBNazim Benzerdjeb
- Ségolène Chagnon-MonarqueSCSégolène Chagnon-Monarque
- Nicolas DionneNDNicolas Dionne
- Guila DelouyaGDGuila Delouya
- André KougioumoutzakisAKAndré Kougioumoutzakis
- Jennifer SiroisJSJennifer Sirois
- Roula AlbadineRARoula Albadine
- Mathieu LatourMLMathieu Latour
- Anne-Marie Mes-MassonAMAnne-Marie Mes-Masson
- Hélène HovingtonHHHélène Hovington
- Alain BergeronABAlain Bergeron
Open Access
- 25 April 2019
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 14 (1) , 60
Abstract
Intraductal carcinoma of the prostate (IDC-P) is an independent biomarker of recurrence and survival with particular treatment response, yet no study has tested its response to radiotherapy. The aim of our project was to test the impact of adjuvant radiotherapy (ART) in patients with localized to locally advanced prostate cancer (PC) and IDC-P. We performed a retrospective study of men with pT2-T3 PC treated by radical prostatectomy (RP) with or without ART, from two centres (1993–2015). Exclusion criteria were the use of another type of treatment prior to biochemical recurrence (BCR), and detectable prostate- specific antigen (PSA) following RP or ART. Primary outcome was BCR (2 consecutive PSA ≥ 0.2 ng/ml). Patients were grouped by treatment (RPonly/RP + ART), IDC-P status, and presence of high-risk features (HRF: Grade Groups 4–5, positive margins, pT3 stage). We reviewed 293 RP specimens (median follow-up 99 months, 69 BCR). Forty-eight patients (16.4%) were treated by RP + ART. Multivariate Cox regression for BCR indicated that IDC-P had the strongest impact (hazard ratio [HR] = 2.39, 95% confidence interval [CI]:1.44–3.97), while ART reduced the risk of BCR (HR = 0.38, 95%CI: 0.17–0.85). Other HRF were all significant except for pT3b stage. IDC-P[+] patients who did not receive ART had the worst BCR-free survival (log-rank P = 0.023). Furthermore, IDC-P had the same impact on BCR-free survival as ≥1 HRF (log-rank P = 0.955). Men with IDC-P who did not receive ART had the highest BCR rates, and IDC-P had the same impact as ≥1 HRF, which are often used as ART indications. Once validated, ART should be considered in patients with IDC-P.Keywords
Funding Information
- Santé
- Canadian Cancer Society
- Institut Du Cancer de Montréal
- Prostate Cancer Canada
This publication has 29 references indexed in Scilit:
- Adjuvant Radiation Following Radical Prostatectomy: What Are the Known Unknowns?European Urology, 2014
- Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 TrialEuropean Urology, 2014
- Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohortEuropean Journal of Cancer, 2014
- Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimensThe Prostate, 2014
- Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the LiteratureEuropean Urology, 2013
- Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)The Lancet, 2012
- Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical TrialJournal of Urology, 2009
- Intraductal carcinoma of the prostate: a distinct histopathological entity with important prognostic implicationsJournal of Clinical Pathology, 2009
- Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significanceLaboratory Investigation, 2006